Novartis bags CDSCO panel nod for Phase 3 trial of Secukimunab

The pharmaceutical major, Novartis, has got a go-ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to conduct the Phase III clinical trial of an immunomodulating agent and interleukin antagonist, Secukimunab.

This approval came after the drug-maker Novartis presented the protocol to conduct the Phase 3 clinical trial of Secukimunab before the committee.

For more information check out the full story on the link below: 

Novartis Gets CDSCO Panel Okay For Phase 3 Trial Of Secukimunab